Dr Dan Gooding, Nuformix, increasingly confident US regulators will grant NXP002 Orphan Drug Status

Nuformix (LON:NFX) targets unmet medical needs in fibrosis and oncology via drug repurposing. 

The pharmaceutical company’s lead programme NXP002 has been granted Orphan Drug Designation in Idiopathic Pulmonary Fibrosis by the European Medical Agency. 

Today, Dr Dan Gooding, Co-founder and Executive Director, explains why he's increasingly confident regulators in the US will also follow suit.

In this interview investors will learn: 

- Why the company specialises in redeveloping known drugs and putting in place new patent protection 

- Who is now involved in the company and what relevant skills they have to progress the business 

- Why the company’s lead programme NXP002 may have the potential to slow the progression of lung fibrosis

- Why the company is increasingly confident US regulators will also grant orphan drug status and what that would mean for Nuformix

- How the company’s other drug development pipelines are progressing 

- When the development partner, to accelerate timelines and treatment administration, is likely to be announced 

Dr Dan Gooding, executive director and co-founder of Nuformix was interviewed by Sarah Lowther for focusIR